Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + Endocrine Therapy in Early-stage HR+/HER2- Breast Cancer
NCT07101159Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2031
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of dalpiciclib in breast cancer, sponsored by Fujian Medical University Cancer Hospital. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07101159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101159.